Amag Pharmaceuticals Inc., of Waltham, Mass., reported record second-quarter sales of $78.4 million for Makena (hydroxyprogesterone caproate injection), approved to lower the risk of pre-term birth, and $24.3 million for Feraheme (ferumoxytol), the iron deficiency anemia drug indicated to treat patients with chronic kidney disease, leading to product and service revenues of $127.4 million on a GAAP basis compared with $123.9 million in the second quarter of 2015 – a period that included $39.2 million of collaboration revenue.